Pediatrix Medical Group, Inc.(MD)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,155 of 2,879 stocksTOP 50%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
MD Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Pediatrix Medical Group, Inc. (MD), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MD at 55.4/100 on a 32-signal composite quality model, placing it at rank #1,155 of 2,879 stocks — the top half of the AI-ranked universe. MD scores in the top quartile across earnings quality (85.9), balance sheet strength (79.0). Areas of concern include revenue growth (24.7) and institutional flow (29.9), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), Pediatrix Medical Group, Inc. reports quarterly revenue of $476.2M, net income of $29.6M, an operating margin of 8.8%. Top institutional holders of MD by reported 13-F value include BlackRock,, VANGUARD PORTFOLIO MANAGEMENT, AMERICAN CENTURY COMPANIES, based on the most recent SEC filings. MD trades on the NYSE exchange and files with the SEC under CIK 893949. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Pediatrix Medical Group, Inc. directly from SEC EDGAR. Pediatrix Medical Group, Inc.'s 13F Pro composite quality score has ranged between 8 and 65 since 2026, currently 55.4 — an improving long-term trajectory across 36 quarterly and live scoring snapshots.
Revenue
Q1 2026
$476.2M
Net Income
Q1 2026
$29.6M
Free Cash Flow
Q1 2026
$-129.8M
Operating Margin
Q1 2026
8.8%
D/E Ratio
Q1 2026
0.67
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+0.9% YoYNet Income
-64.0% YoYOperating Income
-1038.6% YoYEPS (Diluted)
-63.0% YoYTotal Assets
-3.0% YoYTotal Debt
-0.8% YoYOp. Cash Flow
+50.4% YoY| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $2.01B +0.9% | $1.99B +1.1% | $1.97B +3.2% | $1.91B +10.2% | $1.73B -2.6% | $1.78B |
| Net Income | $-99.1M -64.0% | $-60.4M -191.1% | $66.3M -49.3% | $131.0M +116.4% | $-796.5M +46.8% | $-1.50B |
| Operating Income | $-68.7M -1038.6% | $7.3M -95.8% | $172.7M -14.9% | $202.9M +106.8% | $98.1M -42.9% | $171.8M |
| EPS (Diluted) | $-1.19 -63.0% | $-0.73 -192.4% | $0.79 -48.4% | $1.53 +116.0% | $-9.55 +46.4% | $-17.83 |
| Total Assets | $2.15B -3.0% | $2.22B -5.5% | $2.35B -13.8% | $2.72B -18.7% | $3.35B -19.2% | $4.15B |
| Total Debt | $631.7M -0.8% | $637.1M -2.3% | $652.1M -34.3% | $992.2M -41.6% | $1.70B +0.0% | $1.70B |
| Operating Cash Flow | $206.6M +50.4% | $137.3M -17.7% | $166.9M +117.5% | $76.7M -62.5% | $204.6M -42.8% | $357.7M |
AI Insight: MD Financial Trends
Pediatrix returned to profitability after Q2 2024 losses but revenue declined 6% from Q2 2024 to Q1 2026 amid volatile cash flows.
• Revenue declined from $504M in Q2 2024 to $476M in Q1 2026, falling 6% over eight quarters.
• Operating income turned positive, recovering from -$158M loss in Q2 2024 to $42M in Q1 2026.
• Net income improved dramatically from -$153M loss in Q2 2024 to consistent profitability since Q3 2024.
• Total debt surged from $18M in Q2 2024 to $591M in Q1 2026, increasing leverage significantly.
⚠ Operating cash flow turned negative in both Q1 2025 and Q1 2026, showing concerning seasonal pattern.
⚠ Revenue volatility with quarterly swings between $458M and $511M indicates underlying business instability.
AI Insight: MD Ratio Trends
Pediatrix recovered from Q2 2024 losses but margins have declined from Q3 2025 peak of 13.8% to 8.8% in Q1 2026.
• Operating margin recovered from -31.3% loss in Q2 2024 to positive territory, reaching 13.8% peak in Q3 2025.
• Net profit margin swung from -30.3% in Q2 2024 to 14.5% in Q3 2025, demonstrating strong operational turnaround.
• ROE rebounded from -86.6% in Q2 2024 to 32.2% in Q3 2025, indicating improved shareholder returns.
• Debt-to-equity ratio increased substantially from 0.03 in Q3 2024 to 0.67-0.83 range since Q4 2024.
⚠ Operating margin declined from 13.8% peak in Q3 2025 to 8.8% in Q1 2026 — potential momentum loss.
⚠ ROIC dropped from 18.2% in Q3 2025 to 11.3% in Q1 2026, signaling weakening capital efficiency.
Get alerted when MD's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Pediatrix Medical Group, Inc. including:
Top Institutional Holders of MD
BlackRock, Inc.
$290.4M13,574,373 shVANGUARD PORTFOLIO MANAGEMENT LLC
$131.6M6,154,126 shAMERICAN CENTURY COMPANIES INC
$84.0M3,925,366 shDIMENSIONAL FUND ADVISORS LP
$82.5M3,856,915 shVICTORY CAPITAL MANAGEMENT INC
$82.2M3,841,933 shVANGUARD CAPITAL MANAGEMENT LLC
$78.2M3,656,321 shSTATE STREET CORP
$72.3M3,378,500 shFMR LLC
$48.5M2,267,434 shGEODE CAPITAL MANAGEMENT, LLC
$46.8M2,187,967 shWASATCH ADVISORS LP
$43.9M2,050,524 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $290.4M | 13,574,373 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $131.6M | 6,154,126 |
| AMERICAN CENTURY COMPANIES INC | $84.0M | 3,925,366 |
| DIMENSIONAL FUND ADVISORS LP | $82.5M | 3,856,915 |
| VICTORY CAPITAL MANAGEMENT INC | $82.2M | 3,841,933 |
| VANGUARD CAPITAL MANAGEMENT LLC | $78.2M | 3,656,321 |
| STATE STREET CORP | $72.3M | 3,378,500 |
| FMR LLC | $48.5M | 2,267,434 |
| GEODE CAPITAL MANAGEMENT, LLC | $46.8M | 2,187,967 |
| WASATCH ADVISORS LP | $43.9M | 2,050,524 |
More Healthcare Companies
View all Healthcare →Put MD on your watchlist
Track score changes the day Pediatrix Medical Group, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is MD a good stock to buy?
13F Pro's AI-powered analysis of Pediatrix Medical Group, Inc. (MD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MD are available on the MD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own MD?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Pediatrix Medical Group, Inc.'s investment landscape.